Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Oct;149(4):1177–1191.

Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene.

A Tehranian 1, D W Morris 1, B H Min 1, D J Bird 1, R D Cardiff 1, P A Barry 1
PMCID: PMC1865178  PMID: 8863667

Abstract

Male transgenic mice expressing the polyomavirus middle T (PyV-MT) gene exhibited growth and developmental abnormalities in prostatic and other urogenital epithelium. Expression of PyV-MT was directed to these tissues by a novel, androgen-inducible expression vector based on the rat C3(1) gene. Epithelial growth disturbances (hyperplasia, dysplasia, and invasive carcinoma) were observed in the ventral and dorsal prostate, coagulating gland, epididymis, and vas deferens. The abnormalities were characterized by histological disorganization, nuclear pleomorphism, increased mitoses, and abnormal DNA content. Transgene transcription was detected in affected tissues, indicating that the C3(1)-based vector targeted androgen-sensitive urogenital tissues, especially the prostate. These results demonstrated that expression of a gene, the protein of which is known to interact with cellular proteins involved in signal transduction, dramatically disrupted urogenital growth and development.

Full text

PDF
1177

Images in this article

1182Figure 2
on p.1182
1183Figure 3
on p.1183
1184Figure 4
on p.1184
1187Figure 6
on p.1187

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison J., Zhang Y. L., Parker M. G. Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice. Mol Cell Biol. 1989 May;9(5):2254–2257. doi: 10.1128/mcb.9.5.2254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anwar K., Nakakuki K., Shiraishi T., Naiki H., Yatani R., Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 1992 Nov 1;52(21):5991–5996. [PubMed] [Google Scholar]
  3. Auger K. R., Carpenter C. L., Shoelson S. E., Piwnica-Worms H., Cantley L. C. Polyoma virus middle T antigen-pp60c-src complex associates with purified phosphatidylinositol 3-kinase in vitro. J Biol Chem. 1992 Mar 15;267(8):5408–5415. [PubMed] [Google Scholar]
  4. Bacus J. W., Bacus J. V. A method of correcting DNA ploidy measurements in tissue sections. Mod Pathol. 1994 Aug;7(6):652–664. [PubMed] [Google Scholar]
  5. Bolen J. B., Thiele C. J., Israel M. A., Yonemoto W., Lipsich L. A., Brugge J. S. Enhancement of cellular src gene product associated tyrosyl kinase activity following polyoma virus infection and transformation. Cell. 1984 Oct;38(3):767–777. doi: 10.1016/0092-8674(84)90272-1. [DOI] [PubMed] [Google Scholar]
  6. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  7. Buttyan R., Slawin K. Rodent models for targeted oncogenesis of the prostate gland. Cancer Metastasis Rev. 1993 Mar;12(1):11–19. doi: 10.1007/BF00689786. [DOI] [PubMed] [Google Scholar]
  8. Carter B. S., Epstein J. I., Isaacs W. B. ras gene mutations in human prostate cancer. Cancer Res. 1990 Nov 1;50(21):6830–6832. [PubMed] [Google Scholar]
  9. Chastre E., Empereur S., Di Gioia Y., el Mahdani N., Mareel M., Vleminckx K., Van Roy F., Bex V., Emami S., Spandidos D. A. Neoplastic progression of human and rat intestinal cell lines after transfer of the ras and polyoma middle T oncogenes. Gastroenterology. 1993 Dec;105(6):1776–1789. doi: 10.1016/0016-5085(93)91076-t. [DOI] [PubMed] [Google Scholar]
  10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  11. Courtneidge S. A., Smith A. E. Polyoma virus transforming protein associates with the product of the c-src cellular gene. Nature. 1983 Jun 2;303(5916):435–439. doi: 10.1038/303435a0. [DOI] [PubMed] [Google Scholar]
  12. Dilworth S. M. Polyoma virus middle T antigen: meddler or mimic? Trends Microbiol. 1995 Jan;3(1):31–35. doi: 10.1016/s0966-842x(00)88866-6. [DOI] [PubMed] [Google Scholar]
  13. Donjacour A. A., Rosales A., Higgins S. J., Cunha G. R. Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology. 1990 Mar;126(3):1343–1354. doi: 10.1210/endo-126-3-1343. [DOI] [PubMed] [Google Scholar]
  14. Forsslund G., Esposti P. L., Nilsson B., Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer. 1992 Mar 15;69(6):1432–1439. doi: 10.1002/1097-0142(19920315)69:6<1432::aid-cncr2820690621>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  15. Forsslund G., Zetterberg A. Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma. Cancer Res. 1990 Jul 15;50(14):4281–4285. [PubMed] [Google Scholar]
  16. Freund R., Sotnikov A., Bronson R. T., Benjamin T. L. Polyoma virus middle T is essential for virus replication and persistence as well as for tumor induction in mice. Virology. 1992 Dec;191(2):716–723. doi: 10.1016/0042-6822(92)90247-m. [DOI] [PubMed] [Google Scholar]
  17. Greenberg N. M., DeMayo F., Finegold M. J., Medina D., Tilley W. D., Aspinall J. O., Cunha G. R., Donjacour A. A., Matusik R. J., Rosen J. M. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439–3443. doi: 10.1073/pnas.92.8.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gullick W. J., Love S. B., Wright C., Barnes D. M., Gusterson B., Harris A. L., Altman D. G. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991 Mar;63(3):434–438. doi: 10.1038/bjc.1991.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gumerlock P. H., Poonamallee U. R., Meyers F. J., deVere White R. W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 1991 Mar 15;51(6):1632–1637. [PubMed] [Google Scholar]
  20. Guy C. T., Cardiff R. D., Muller W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992 Mar;12(3):954–961. doi: 10.1128/mcb.12.3.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Guy C. T., Muthuswamy S. K., Cardiff R. D., Soriano P., Muller W. J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 1994 Jan;8(1):23–32. doi: 10.1101/gad.8.1.23. [DOI] [PubMed] [Google Scholar]
  22. Guy C. T., Webster M. A., Schaller M., Parsons T. J., Cardiff R. D., Muller W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578–10582. doi: 10.1073/pnas.89.22.10578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hill C. S., Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 1995 Jan 27;80(2):199–211. doi: 10.1016/0092-8674(95)90403-4. [DOI] [PubMed] [Google Scholar]
  24. Ho S. N., Hunt H. D., Horton R. M., Pullen J. K., Pease L. R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989 Apr 15;77(1):51–59. doi: 10.1016/0378-1119(89)90358-2. [DOI] [PubMed] [Google Scholar]
  25. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995 Jan 27;80(2):225–236. doi: 10.1016/0092-8674(95)90405-0. [DOI] [PubMed] [Google Scholar]
  26. Hurst H. C., Parker M. G. Rat prostatic steroid binding protein: DNA sequence and transcript maps of the two C3 genes. EMBO J. 1983;2(5):769–774. doi: 10.1002/j.1460-2075.1983.tb01498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Isaacs J. T. Prostatic cancer: an age-old problem. Adv Exp Med Biol. 1993;330:167–184. doi: 10.1007/978-1-4615-2926-2_13. [DOI] [PubMed] [Google Scholar]
  28. Jacobs C., Rübsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983 Apr;43(4):1696–1702. [PubMed] [Google Scholar]
  29. Johnson G. L., Vaillancourt R. R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol. 1994 Apr;6(2):230–238. doi: 10.1016/0955-0674(94)90141-4. [DOI] [PubMed] [Google Scholar]
  30. Konishi N., Enomoto T., Buzard G., Ohshima M., Ward J. M., Rice J. M. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer. 1992 May 1;69(9):2293–2299. doi: 10.1002/1097-0142(19920501)69:9<2293::aid-cncr2820690915>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  31. Kuhn E. J., Kurnot R. A., Sesterhenn I. A., Chang E. H., Moul J. W. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol. 1993 Nov;150(5 Pt 1):1427–1433. doi: 10.1016/s0022-5347(17)35799-3. [DOI] [PubMed] [Google Scholar]
  32. Maroulakou I. G., Anver M., Garrett L., Green J. E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236–11240. doi: 10.1073/pnas.91.23.11236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Marshall C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995 Jan 27;80(2):179–185. doi: 10.1016/0092-8674(95)90401-8. [DOI] [PubMed] [Google Scholar]
  34. Mills J. S., Needham M., Thompson T. C., Parker M. G. Androgen-regulated expression of secretory protein synthesis in mouse ventral prostate. Mol Cell Endocrinol. 1987 Sep;53(1-2):111–118. doi: 10.1016/0303-7207(87)90197-3. [DOI] [PubMed] [Google Scholar]
  35. Montgomery B. T., Nativ O., Blute M. L., Farrow G. M., Myers R. P., Zincke H., Therneau T. M., Lieber M. M. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg. 1990 Mar;125(3):327–331. doi: 10.1001/archsurg.1990.01410150049010. [DOI] [PubMed] [Google Scholar]
  36. Moul J. W., Friedrichs P. A., Lance R. S., Theune S. M., Chang E. H. Infrequent RAS oncogene mutations in human prostate cancer. Prostate. 1992;20(4):327–338. doi: 10.1002/pros.2990200407. [DOI] [PubMed] [Google Scholar]
  37. Muller W. J., Sinn E., Pattengale P. K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988 Jul 1;54(1):105–115. doi: 10.1016/0092-8674(88)90184-5. [DOI] [PubMed] [Google Scholar]
  38. Nagel R., al Abadi H. The prognostic significance of ploidy and DNA-heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma. Scand J Urol Nephrol Suppl. 1991;138:83–92. [PubMed] [Google Scholar]
  39. Nativ O., Winkler H. Z., Raz Y., Therneau T. M., Farrow G. M., Myers R. P., Zincke H., Lieber M. M. Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc. 1989 Aug;64(8):911–919. doi: 10.1016/s0025-6196(12)61218-x. [DOI] [PubMed] [Google Scholar]
  40. Ono M., Kuwano M., Kung H. F. Malignant transformation of mouse BALB/3T3 cells by polyoma middle T antigen requires epidermal growth factor receptor expression. Cell Growth Differ. 1991 Jul;2(7):317–322. [PubMed] [Google Scholar]
  41. Ottenhoff-Kalff A. E., Rijksen G., van Beurden E. A., Hennipman A., Michels A. A., Staal G. E. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 1992 Sep 1;52(17):4773–4778. [PubMed] [Google Scholar]
  42. Parker M. G., Scrace G. T., Mainwaring W. I. Testosterone regulates the synthesis of major proteins in rat ventral prostate. Biochem J. 1978 Jan 15;170(1):115–121. doi: 10.1042/bj1700115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Parker M. G., Scrace G. T. The androgenic regulation of abundant mRNA in rat ventral prostate. Eur J Biochem. 1978 Apr 17;85(2):399–406. doi: 10.1111/j.1432-1033.1978.tb12252.x. [DOI] [PubMed] [Google Scholar]
  44. Parker M. G., White R., Williams J. G. Cloning and characterization of androgen-dependent mRNA from rat ventral prostate. J Biol Chem. 1980 Jul 25;255(14):6996–7001. [PubMed] [Google Scholar]
  45. Paterson M. C., Dietrich K. D., Danyluk J., Paterson A. H., Lees A. W., Jamil N., Hanson J., Jenkins H., Krause B. E., McBlain W. A. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991 Jan 15;51(2):556–567. [PubMed] [Google Scholar]
  46. Peehl D. M., Wehner N., Stamey T. A. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate. 1987;10(4):281–289. doi: 10.1002/pros.2990100402. [DOI] [PubMed] [Google Scholar]
  47. Pergolizzi R. G., Kreis W., Rottach C., Susin M., Broome J. D. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest. 1993;11(1):25–32. doi: 10.3109/07357909309020257. [DOI] [PubMed] [Google Scholar]
  48. Peters J. M., Miles B. J., Kubus J. J., Crissman J. D. Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. Anal Quant Cytol Histol. 1990 Oct;12(5):359–365. [PubMed] [Google Scholar]
  49. Rainwater L. M., Zincke H. Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol. 1988 Dec;140(6):1455–1459. doi: 10.1016/s0022-5347(17)42072-6. [DOI] [PubMed] [Google Scholar]
  50. Rassoulzadegan M., Courtneidge S. A., Loubière R., el Baze P., Cuzin F. A variety of tumours induced by the middle T antigen of polyoma virus in a transgenic mouse family. Oncogene. 1990 Oct;5(10):1507–1510. [PubMed] [Google Scholar]
  51. Rosen N., Bolen J. B., Schwartz A. M., Cohen P., DeSeau V., Israel M. A. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem. 1986 Oct 15;261(29):13754–13759. [PubMed] [Google Scholar]
  52. Sadasivan R., Morgan R., Jennings S., Austenfeld M., Van Veldhuizen P., Stephens R., Noble M. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol. 1993 Jul;150(1):126–131. doi: 10.1016/s0022-5347(17)35413-7. [DOI] [PubMed] [Google Scholar]
  53. Shankey T. V., Kallioniemi O. P., Koslowski J. M., Lieber M. L., Mayall B. H., Miller G., Smith G. J. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry. 1993;14(5):497–500. doi: 10.1002/cyto.990140508. [DOI] [PubMed] [Google Scholar]
  54. Singleton T. P., Strickler J. G. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu. 1992;27(Pt 1):165–190. [PubMed] [Google Scholar]
  55. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  56. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  57. Song J., Cheng W. S., Cupps R. E., Earle J. D., Farrow G. M., Lieber M. M. Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol. 1992 Mar;147(3 Pt 2):794–797. doi: 10.1016/s0022-5347(17)37388-3. [DOI] [PubMed] [Google Scholar]
  58. Tan J. A., Marschke K. B., Ho K. C., Perry S. T., Wilson E. M., French F. S. Response elements of the androgen-regulated C3 gene. J Biol Chem. 1992 Mar 5;267(7):4456–4466. [PubMed] [Google Scholar]
  59. Tischler A. S., Freund R., Carroll J., Cahill A. L., Perlman R. L., Alroy J., Riseberg J. C. Polyoma-induced neoplasms of the mouse adrenal medulla. Characterization of the tumors and establishment of cell lines. Lab Invest. 1993 May;68(5):541–549. [PubMed] [Google Scholar]
  60. Tribukait B. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology. Acta Oncol. 1991;30(2):187–192. doi: 10.3109/02841869109092348. [DOI] [PubMed] [Google Scholar]
  61. Tutrone R. F., Jr, Ball R. A., Ornitz D. M., Leder P., Richie J. P. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J Urol. 1993 Mar;149(3):633–639. doi: 10.1016/s0022-5347(17)36169-4. [DOI] [PubMed] [Google Scholar]
  62. Yokota J., Yamamoto T., Toyoshima K., Terada M., Sugimura T., Battifora H., Cline M. J. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986 Apr 5;1(8484):765–767. doi: 10.1016/s0140-6736(86)91782-4. [DOI] [PubMed] [Google Scholar]
  63. Zetterberg A., Forsslund G. Ploidy level and tumor progression in prostatic carcinoma. Acta Oncol. 1991;30(2):193–199. doi: 10.3109/02841869109092349. [DOI] [PubMed] [Google Scholar]
  64. Zincke H., Bergstralh E. J., Larson-Keller J. J., Farrow G. M., Myers R. P., Lieber M. M., Barrett D. M., Rife C. C., Gonchoroff N. J. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer. 1992 Jul 1;70(1 Suppl):311–323. doi: 10.1002/1097-0142(19920701)70:1+<311::aid-cncr2820701320>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  65. al-Abadi H., Nagel R. Nuclear DNA analysis: the relevance of ploidy, DNA heterogeneity and phases of the cell cycle in 329 patients with prostatic carcinoma. A study on a follow-up of eight years. Urol Int. 1990;45(6):350–355. doi: 10.1159/000281736. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES